Production (Stage)
Nektar Therapeutics
NKTR
$0.666
-$0.0088-1.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.46M | 29.18M | 24.12M | 23.49M | 21.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.46M | 29.18M | 24.12M | 23.49M | 21.64M |
| Cost of Revenue | -- | 7.98M | 4.44M | 9.74M | 8.53M |
| Gross Profit | 10.46M | 21.20M | 19.69M | 13.75M | 13.11M |
| SG&A Expenses | 24.35M | 17.14M | 18.96M | 20.51M | 20.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.83M | 53.86M | 58.42M | 59.97M | 56.09M |
| Operating Income | -44.37M | -24.68M | -34.30M | -36.49M | -34.45M |
| Income Before Tax | -50.83M | 7.00M | -37.05M | -52.32M | -36.84M |
| Income Tax Expenses | 52.00K | -259.00K | 9.00K | 46.00K | -35.00K |
| Earnings from Continuing Operations | -50.88M | 7.26M | -37.06M | -52.36M | -36.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.88M | 7.26M | -37.06M | -52.36M | -36.80M |
| EBIT | -44.37M | -24.68M | -34.30M | -36.49M | -34.45M |
| EBITDA | -43.94M | -24.35M | -33.31M | -35.03M | -32.85M |
| EPS Basic | -0.24 | 0.03 | -0.18 | -0.25 | -0.19 |
| Normalized Basic EPS | -0.15 | -0.10 | -0.11 | -0.12 | -0.12 |
| EPS Diluted | -0.24 | 0.03 | -0.18 | -0.25 | -0.19 |
| Normalized Diluted EPS | -0.15 | -0.09 | -0.11 | -0.12 | -0.12 |
| Average Basic Shares Outstanding | 210.92M | 209.74M | 209.25M | 208.83M | 194.75M |
| Average Diluted Shares Outstanding | 210.92M | 213.59M | 209.25M | 208.83M | 194.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |